DENVER, July 9 /PRNewswire-FirstCall/ — Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, will be exhibiting its AspirinWorks(R) Test at the XXII Congress and the 55th Meeting of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (ISTH). The ISTH 2009 conference is being held July 11-16 at the Boston Convention & Exhibition Center.
AspirinWorks is a simple urine test that determines the effect of aspirin on platelets by measuring the level of thromboxane production (aspirin’s target). The higher the levels of thromboxane, the stickier the blood platelets and the less impact the aspirin is having. This crucial information may allow physicians to individualize a patient’s therapy.
Unlike other platelet tests, which require freshly drawn blood that must be evaluated within at least four hours, the AspirinWorks Test requires only a random urine sample that can be obtained in any doctor’s office or patient service center, making the test easy for both the physician and patient.
“Our participation in the ISTH conference marks an excellent opportunity for Corgenix to discuss the importance of accurately testing for individual aspirin response in an international arena,” said Corgenix’ Clinical Affairs Director Gordon Ens.
The AspirinWorks Test, which was launched in the United States in June 2007 following FDA 510(k) clearance, is now available nationwide through major medical reference laboratories as well as direct to consumers through HealthCheckUSA (www.HealthCheckUSA.com).
The AspirinWorks Test Kit is an enzyme-linked immunoassay (ELISA) to determine levels of 11dehydro Thromboxane B2 (11dhTxB2) in human urine, which aids in the qualitative detection of aspirin effect in apparently healthy individuals post ingestion. The test targets a potential U.S. market of over 60 million individuals and a potential global market exceeding 200 million individuals who take aspirin regularly.
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at www.corgenix.com.
Statements in this press release that are not strictly historical facts are “forward looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.
SOURCE Corgenix Medical Corporation
HealthCheckUSA is the nation’s leader in low cost, direct-to-consumer blood and lab testing and provides people the ability to access all types of blood tests without a physician’s referral and at half the price.
HealthCheckUSA has packages that make it simple for consumers to measure, monitor, and improve their health by being able to order their own lab tests without a doctor’s order. HealthCheckUSA serves customers without insurance, have high deductible insurance plans, and taking control of their health because their doctor won’t order the test.
The tests available through HealthCheckUSA are the same medically accepted lab tests ordered by doctors for their patients. The tests are analyzed by an accredited medical reference laboratory. The results are confidential, and are available by fax to you or your doctor, or by mail to you (please allow 10 working days for mailing). Results are also available on the HealthCheckUSA Web site within 3-4 business days. An information sheet with an explanation of each test, including normal reference ranges, accompanies all results.